OSI Systems, Inc. — Form 10-Q Summary
Business context and reporting period
OSI Systems designs and manufactures specialized electronic systems and components for security and inspection, healthcare, defense, aerospace, and related markets. Its operating segments are Security, Healthcare, and Optoelectronics and Manufacturing.
This filing covers the quarter and six months ended December 31, 2022, representing the second quarter and first six months of fiscal 2023. The financial statements are unaudited and presented under U.S. GAAP.
Key financial metrics
| Metric | Three months ended Dec. 31, 2022 | Year-over-year change | Six months ended Dec. 31, 2022 | Year-over-year change |
|---|---|---|---|---|
| Net revenues | $295.6 million | Up 7% | $563.7 million | Up 1% |
| Gross profit | $96.2 million | Down from $99.8 million | $183.7 million | Down from $199.1 million |
| Gross margin | 32.5% | Down from 36.1% | 32.6% | Down from 35.8% |
| Income from operations | $25.5 million | Down from $29.1 million | $43.8 million | Down from $53.8 million |
| Net income | $16.4 million | Down from $19.8 million | $27.6 million | Down from $38.8 million |
| Diluted EPS | $0.96 | Down from $1.09 | $1.61 | Down from $2.13 |
| Cash flow from operations | Not separately provided | — | $8.2 million | Up from $3.4 million |
Six-month operating margin was approximately 7.8%, compared with 9.7% in the prior-year period. Six-month net margin was approximately 4.9%, compared with 7.0% previously. Interest and other expense increased to $8.6 million from $4.2 million for the six-month period, primarily because of higher interest rates and increased borrowings.
Segment performance and material changes
- Security: Six-month revenue increased 6% to $312.4 million and represented 55% of consolidated revenue. Growth was driven primarily by cargo and vehicle inspection systems, partially offset by lower aviation revenue. Second-quarter revenue increased 15% to $167.4 million.
- Healthcare: Six-month revenue decreased 15% to $87.1 million. Patient monitoring and cardiology sales declined, partly because the prior-year period benefited from elevated COVID-19-related demand. Second-quarter revenue decreased 17% to $43.5 million.
- Optoelectronics and Manufacturing: Six-month revenue increased 4% to $164.1 million, driven primarily by growth in optoelectronics. Second-quarter revenue increased 8% to $84.7 million.
- Margins: Gross margin declined because of unfavorable Security product mix, higher component and raw-material costs, lower Healthcare revenue, and a greater contribution from the lower-margin Optoelectronics and Manufacturing segment.
- Operating expenses: Six-month SG&A declined 4% to $107.4 million and research and development declined 3% to $29.0 million. Restructuring and other charges increased slightly to $3.5 million, including approximately $2.9 million of legal charges primarily related to government investigations.
- Capital allocation: The company repurchased 261,761 shares for $21.8 million during the six months. The September 2022 authorization permits repurchase of up to 2 million shares, with 1,860,339 shares remaining available at December 31, 2022.
Cash, debt, liquidity, and unusual items
- Cash and cash equivalents were $45.6 million at December 31, 2022, down from $64.2 million at June 30, 2022. Approximately 98% was held by foreign subsidiaries and may be subject to repatriation tax considerations.
- The company generated $8.2 million of operating cash flow and used $18.9 million in investing activities, including $7.0 million of capital expenditures, $8.0 million for intangible and other assets, and $3.5 million for acquisitions.
- Financing activities used $3.7 million of cash. The company repurchased and canceled $242.3 million of 1.25% convertible notes due September 2022 using proceeds from its senior secured credit facility.
- At December 31, 2022, the company had $235.0 million outstanding under its revolving credit facility, $146.9 million under its term loan, and $66.8 million of letters of credit. Reported availability under the credit facilities was $298.2 million, and the company was in compliance with its financial covenants.
- The credit facility matures in December 2026. Borrowings carried interest at SOFR plus a 1.25% margin at quarter-end. An interest-rate swap with a $175 million notional amount was entered into in September 2022 and had a fair value of approximately $3.3 million at December 31, 2022.
- Remaining performance obligations were approximately $338.9 million, with approximately 58% expected to be recognized as revenue over the next 12 months.
- The company completed two fiscal 2023 Security acquisitions for approximately $3.5 million in aggregate. These acquisitions were not material individually or in aggregate.
Outlook, risks, contingencies, and management commentary
Management stated that available cash, credit facilities, and expected operating cash flow should be sufficient to meet operational needs for the next 12 months and the foreseeable future. No specific revenue or earnings guidance was provided in the filing.
- COVID-19 continues to present risks involving supply-chain disruptions, labor availability, facility operations, customer delivery schedules, acceptance testing, and demand. Earlier pandemic-related demand in Healthcare has also created difficult comparisons.
- Supply shortages, longer lead times, freight constraints, inflation, rising interest rates, and labor shortages may pressure costs and margins.
- The Russia-Ukraine conflict and related sanctions increase geopolitical, cyber, supply-chain, and economic risks. The company reported some impact to Healthcare research and development activities in Ukraine but no significant adverse impact to date.
- Foreign exchange movements reduced reported six-month sales by approximately 1.7% year over year, primarily because of U.S. dollar strength.
- The company faces potential legal, regulatory, export-control, environmental, compliance, and government-investigation risks. It recorded legal charges but did not accrue for certain legal or environmental loss contingencies because unfavorable outcomes were not considered probable and reasonably estimable.
- Capped acquisition-related contingent consideration obligations had a maximum remaining potential payment of $50.0 million at December 31, 2022; the recorded contingent consideration liability was approximately $22.7 million.
- The company has a $13.5 million employment-related bonus obligation to the CEO, payable in or within 45 days of January 1, 2024, subject to continued employment and certain accelerated payout provisions.
- Management reported effective disclosure controls and procedures and no material changes to internal control over financial reporting during the quarter. The filing states that there were no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Whether Security revenue growth, particularly in cargo and vehicle inspection, can offset continued weakness or volatility in aviation and Healthcare demand.
- Whether gross margins recover from the 32.5% quarterly and 32.6% year-to-date levels as supply-chain costs, product mix, and component availability change.
- The effect of higher SOFR-based borrowing costs on earnings and cash flow, despite the new interest-rate swap.
- Liquidity and refinancing exposure given $381.9 million of revolving and term-loan borrowings, $66.8 million of letters of credit, and significant cash held offshore.
- The timing and outcome of government investigations, legal matters, environmental contingencies, and related unaccrued potential liabilities.
- Progress toward converting the $338.9 million remaining performance obligation balance into revenue and cash.
- The impact of COVID-19, geopolitical conflict, foreign exchange, supply-chain constraints, inflation, and customer acceptance timing on future results.